Changchun GeneScience Pharmaceutical Co., Ltd.

🇨🇳China

Country: 🇨🇳China

Ownership: -

Established: 1948-01-01

Employees: -

Market Cap: -

Website: http://english.ciac.cas.cn/

Clinical Trials

Safety and Efficacy of Genakumab for Injection in Patients With Gout Initiating Urico-lowering Therapy

Phase 2

Completed

Conditions: Acute Gout
Gout Initiating Urico-lowering Therapy

Interventions: Drug: Genakumab for injection
Drug: Etoricorxib

First Posted Date: 2023-07-07

Last Posted Date: 2024-11-08

Lead Sponsor: Changchun GeneScience Pharmaceutical Co., Ltd.

Target Recruit Count: 106

Registration Number: NCT05936281

Locations: 🇨🇳
Fudan University Affiliated Huashan Hospital, Shanghai, Shanghai, China

Safety and Efficacy of Genakumab for Injection in Patients With Gout Flare

Phase 2

Completed

Conditions: Acute Gout
Gout Flare

Interventions: Drug: Genakumab for injection
Drug: Colchicine

First Posted Date: 2023-07-07

Last Posted Date: 2024-11-08

Lead Sponsor: Changchun GeneScience Pharmaceutical Co., Ltd.

Target Recruit Count: 106

Registration Number: NCT05936268

Locations: 🇨🇳
Fudan University Affiliated Huashan Hospital, Shanghai, Shanghai, China

To Evaluate the Efficacy and Safety of Genalumab for Injection in the Treatment of Active Systemic Juvenile Idiopathic Arthritis.

Phase 2

Not yet recruiting

Conditions: Active Systemic Juvenile Idiopathic Arthritis

Interventions: Drug: GenaKumab

First Posted Date: 2023-06-29

Last Posted Date: 2023-07-07

Lead Sponsor: Changchun GeneScience Pharmaceutical Co., Ltd.

Target Recruit Count: 30

Registration Number: NCT05925452

Locations: 🇨🇳
Children's Hospital Affiliated to Capital Medical University, Beijing, Benjing, China
🇨🇳
Children's Hospital Affiliated to Chongqing Medical University, Chongqing, Chongqing, China
🇨🇳
Hunan Children's Hospital, Changsha, Hunan, China

and more 7 locations

To Evaluate the Safety and Tolerability of Multiple Doses of GS3-007a Oral Solution in Healthy Subjects.

Phase 1

Completed

Conditions: Healthy Subject

Interventions: Drug: GS3-007 oral liquid

First Posted Date: 2023-06-27

Last Posted Date: 2023-11-09

Lead Sponsor: Changchun GeneScience Pharmaceutical Co., Ltd.

Target Recruit Count: 36

Registration Number: NCT05921890

Locations: 🇨🇳
Chengdu Xinhua Hospital Affiliated to North Sichuan Medical College, Chengdu, Sichuan, China

Gentuximab Combined With Paclitaxel Compared With Placebo Combined With Paclitaxel for Gastric Adenocarcinoma.

Phase 3

Recruiting

Conditions: Adenocarcinoma of Stomach

Interventions: Drug: Gentuximab Injection
Drug: Gentuximab Injection Placebo

First Posted Date: 2023-06-26

Last Posted Date: 2023-06-26

Lead Sponsor: Changchun GeneScience Pharmaceutical Co., Ltd.

Target Recruit Count: 752

Registration Number: NCT05919381

Locations: 🇨🇳
Shanghai Dongfang Hospital, Shanghai, Shanghai, China

Clinical Study of Multiple Dose Genakumab for Injection in Chinese Healthy Adults

Phase 1

Recruiting

Conditions: Interstitial Lung Disease

Interventions: Drug: Genakumab injection
Drug: placebo

First Posted Date: 2023-06-08

Last Posted Date: 2023-06-08

Lead Sponsor: Changchun GeneScience Pharmaceutical Co., Ltd.

Target Recruit Count: 24

Registration Number: NCT05894148

Locations: 🇨🇳
Chengdu Xinhua Hospital Affiliated to North Sichuan Medical College, Chengdu, Sichuan, China

A Phase 2, Randomized, Placebo-controlled, Double-blind Study of EG017 in Female Patients With Stress Urinary Incontinence

Phase 2

Completed

Conditions: Stress Urinary Incontinence

Interventions: Drug: EG017 3mg
Drug: EG017 6mg

First Posted Date: 2023-01-06

Last Posted Date: 2023-01-06

Lead Sponsor: Changchun GeneScience Pharmaceutical Co., Ltd.

Target Recruit Count: 51

Registration Number: NCT05674045

Locations: 🇨🇳
People's Hospital of Peking University, Beijing, Beijing, China

To Evaluate a Phase Ia/Ib Clinical Study of EG017 in Patients With Advanced Breast Cancer.

Phase 1

Recruiting

Conditions: Breast Cancer

Interventions: Drug: EG017

First Posted Date: 2023-01-06

Last Posted Date: 2023-12-14

Lead Sponsor: Changchun GeneScience Pharmaceutical Co., Ltd.

Target Recruit Count: 70

Registration Number: NCT05673694

Locations: 🇨🇳
First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China
🇨🇳
Cancer Hospital of CAMS, Beijing, Benjing, China
🇨🇳
Henan Cancer Hospital, Zhengzhou, Henan, China

and more 2 locations

GS3-007a Oral Solution in Healthy Subjects

Phase 1

Completed

Conditions: Healthy Subject

Interventions: Drug: GS3-007 oral liquid or Placebo GS3-007 oral liquid oral medication

First Posted Date: 2022-11-10

Last Posted Date: 2023-04-11

Lead Sponsor: Changchun GeneScience Pharmaceutical Co., Ltd.

Target Recruit Count: 96

Registration Number: NCT05611281

Locations: 🇨🇳
Chengdu Xinhua Hospital Affiliated to North Sichuan Medical College, Chengdu, Chengdu, China

Genakumab Alone and in Combination With Tislelizumab in Patients With Advanced Malignant Solid Tumors

Phase 1

Recruiting

Conditions: Malignant Solid Tumors

Interventions: Drug: Genakumab

First Posted Date: 2022-07-01

Last Posted Date: 2022-07-06

Lead Sponsor: Changchun GeneScience Pharmaceutical Co., Ltd.

Target Recruit Count: 120

Registration Number: NCT05441046

Locations: 🇨🇳
Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy